Dr. Carbone on the Importance of Personalizing Immunotherapy in NSCLC

Video

David P. Carbone, MD, PhD, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer.

David P. Carbone, MD, PhD, director of the Thoracic Oncology Center; a professor in the Division of Medical Oncology; co-leader of the Translational Therapeutics Program; and Barbara J. Bonner Chair in Lung Cancer Research, at The Ohio State University Comprehensive Cancer Center—James, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer (NSCLC).

The role of precision medicine has seen rapid progress in lung cancer, says Carbone. The field continues to move toward matching individual patients with targeted therapies based on biomarkers.

However, the high response rates that have been seen with immunotherapy in lung cancer poses the risk of reverting to a one-size-fits-all treatment approach where all patients receive the same immunotherapeutic regimen, explains Carbone.

It is important to select which patients should receive immunotherapy based on their likelihood of response, says Carbone. Research in this regard could shed light on novel therapies or combinations that could have utility in specific patient populations, concludes Carbone.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,